A phase I-II study to evaluate the efficacy and safety of niraparib in combination with cabozantinib (XL184) in patients with advanced urothelial cancer after failure to first-line platinum-based chemotherapy
Tipus: ASSAIG CLÍNIC Autor: nÚria sala gonzÁlez Centre: Institut Català d'Oncologia (ICO)A Phase I/IIa, Open-label, Multi-center Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of the ATR Kinase Inhibitor ART0380 Administered Orally as Monotherapy and in Combination to Patients with Advanced or Metastatic Solid Tumors
Tipus: ASSAIG CLÍNIC Autor: pilar barretina ginesta Centre: Institut Català d'Oncologia (ICO)A PHASE Ib STUDY OF COBIMETINIB ADMINISTERED IN COMBINATION WITH NIRAPARIB, WITH OR WITHOUT ATEZOLIZUMAB, TO PATIENTS WITH ADVANCED PLATINUM-SENSITIVE OVARIAN CANCER
Tipus: ASSAIG CLÍNIC Autor: pilar barretina ginesta Centre: Institut Català d'Oncologia (ICO)A Phase II Multi-Arm (basket) Trial Investigating the Safety and Efficacy of IO102-IO103 in Combination with Pembrolizumab, as First-line Treatment for Patients with Metastatic Non-Small Cell Lung Cancer (NSCLC), Squamous Cell Carcinoma of Head and Neck (SCCHN), or Metastatic Urothelial Bladder Cancer (mUBC)
Tipus: ASSAIG CLÍNIC Autor: joaquim bosch barrera Centre: Institut Català d'Oncologia (ICO)A phase II prospective, open-label, multi-centre, single arm study of sasanlimab plus sacituzumab govitecan in BCG-unresponsive NMIBC patients (SSANTROP)
Tipus: ASSAIG CLÍNIC Autor: josep maria comet batlle Centre: Hospital Universitari Dr.Josep TruetaA PHASE II TRIAL OF ATEZOLIZUMAB PLUS INDUCTION CHEMOTHERAPY (CT) PLUS CHEMO-RADIOTHERAPY AND ATEZOLIZUMAB MAINTENANCE THERAPY IN NON-RESECTABLE STAGE IIIA-IIIB NON-SMALL CELL LUNG CANCER (NSCLC) PATIENTS
Tipus: ASSAIG CLÍNIC Autor: joaquim bosch barrera Centre: Institut Català d'Oncologia (ICO)A PHASE II TRIAL OF NEOADJUVANT TREATMENT CARBOPLATIN-PEMETREXED-BEVACIZUMAB PLUS ATEZOLIZUMAB FOR THE TREATMENT OF LOCALLY ADVANCED AND POTENTIALLY RESECTABLE NSCLC PATIENTS WITH EGFR MUTATIONS
Tipus: ASSAIG CLÍNIC Autor: joaquim bosch barrera Centre: Institut Català d'Oncologia (ICO)A Phase II, randomised, multi-centric, multi-national clinical trial to evaluate the efficacy, tolerability, and safety of a fixed dose combination of Spironolactone, Pioglitazone & Metformin (SPIOMET) for adolescent girls and young adult women (AYAs) with polycystic ovary syndrome (PCOS)
Tipus: ASSAIG CLÍNIC Autor: abel lÓpez bermejo Centre: Hospital Universitari Dr.Josep TruetaA phase II, randomized, double-blind, multi-centre trial to evaluate the safety and immunogenicity of BIMERVAX® when coadministered with seasonal surface antigen, inactivated, adjuvanted influenza vaccine (SIIV) in adults older than 65 years of age.
Tipus: ASSAIG CLÍNIC Autor: antoni castro guardiola Centre: Hospital Universitari Dr.Josep TruetaA Phase II/III, Randomised, Multicentre Study of MOR00208 with Bendamustine versus Rituximab with Bendamustine in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (R-R DLBCL) Who Are Not Eligible for High-Dose Chemotherapy (HDC) and Autologous Stem-Cell Transplantation (ASCT)
Tipus: ASSAIG CLÍNIC Autor: josep maria roncero vidal Centre: Institut Català d'Oncologia (ICO)A PHASE III CLINICAL TRIAL OF ADJUVANT CHEMOTHERAPY VS CHEMO-IMMUNOTHERAPY FOR STAGE IB-IIIA COMPLETELY RESECTED NON-SMALL CELL LUNG CANCER (NSCLC) PATIENTS
Tipus: ASSAIG CLÍNIC Autor: joaquim bosch barrera Centre: Institut Català d'Oncologia (ICO)A phase III open-label, multicenter, randomized trial of adjuvant palbociclib in combination with endocrine therapy versus endocrine therapy alone for patients with hormone receptor positive / HER2-negative resected isolated locoregional recurrence of breast cancer
Tipus: ASSAIG CLÍNIC Autor: sonia del barco berron Centre: Institut Català d'Oncologia (ICO)A phase III randomized trial of post-operative adjuvant nivolumab and concomitant chemo-radiotherapy in high-risk patients with resected squamous cell carcinoma of head and neck (SCCHN)
Tipus: ASSAIG CLÍNIC Autor: jordi rubiÓ casadevall Centre: Institut Català d'Oncologia (ICO)A phase III randomized, double-blinded trial of platinum-based chemotherapy with or without atezolizumab followed by niraparib maintenance with or without atezolizumab in patients with recurrent ovarian, tubal or peritoneal cancer and platinum treatment-free interval (TFIp) >6 months
Tipus: ASSAIG CLÍNIC Autor: pilar barretina ginesta Centre: Institut Català d'Oncologia (ICO)A Phase III, Randomised, Open-Label Study of Savolitinib in Combination With Osimertinib Versus Platinum-Based Doublet Chemotherapy in Participants With EGFR Mutated METOverexpressed and/or Amplified, Locally Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Progressed on Treatment With Osimertinib (SAFFRON)
Tipus: ASSAIG CLÍNIC Autor: joaquim bosch barrera Centre: Institut Català d'Oncologia (ICO)A Phase IIIb, Open-label, Single-arm, Global Study of Perioperative Durvalumab With Neoadjuvant ddMVAC or Gem/Cis in Patients With Muscle-Invasive Bladder Cancer (NIAGARA-2)
Tipus: ASSAIG CLÍNIC Autor: nÚria sala gonzÁlez Centre: Institut Català d'Oncologia (ICO)A pivotal, multicentre, randomised, open-label, parallel-group trial on contraceptive efficacy, safety and tolerability of LVDS (Levonorgestrel Vaginal Delivery System) during 9 cycles in comparison with Desogestrel tablets 0.075 mg
Tipus: ASSAIG CLÍNIC Autor: anna maroto gonzalez Centre: Hospital Universitari Dr.Josep TruetaA prospective single-blind RCT on the effectiveness of quadripolar intravaginal radiofrequency for the treatment of overactive bladder symptoms
Tipus: ASSAIG CLÍNIC Autor: joan melendez muÑoz Centre: Hospital Universitari Dr.Josep TruetaA Prospective, Multi-center Registry for Patients with Short Bowel Syndrome
Tipus: ESTUDI OBSERVACIONAL Autor: silvia mauri roca Centre: Hospital Universitari Dr.Josep TruetaA Prospective, Open-Label, Randomized, Phase 3 Trial of Acasunlimab (GEN1046) in Combination With Pembrolizumab Versus Docetaxel in Subjects With PD-L1 Positive Metastatic Non-Small Cell Lung Cancer After Treatment With a PD-1/PD-L1 Inhibitor and Platinum-Containing Chemotherapy (ABBIL1TY NSCLC-06)
Tipus: ASSAIG CLÍNIC Autor: joaquim bosch barrera Centre: Institut Català d'Oncologia (ICO)